Michael King - SAB Biotherapeutics EVP CFO
CFO
Michael King is EVP CFO of SAB Biotherapeutics
| Age | 63 |
| Phone | 605 679 6980 |
| Web | https://www.sabbiotherapeutics.com |
Michael King Latest Insider Activity
Tracking and analyzing the buying and selling activities of Michael King against SAB Biotherapeutics stock is an integral part of due diligence when investing in SAB Biotherapeutics. Michael King insider activity provides valuable insight into whether SAB Biotherapeutics is net buyers or sellers over its current business cycle. Note, SAB Biotherapeutics insiders must abide by specific rules, including filing SEC forms every time they buy or sell SAB Biotherapeutics'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Michael King over a year ago Disposition of 27371 shares by Michael King of Pactiv Evergreen at 13.23 subject to Rule 16b-3 | ||
Michael King over a year ago Payment of 49335 shares by Michael King of Pactiv Evergreen subject to Rule 16b-3 |
SAB Biotherapeutics Management Efficiency
The company has return on total asset (ROA) of (0.788) % which means that it has lost $0.788 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.7473) %, meaning that it created substantial loss on money invested by shareholders. SAB Biotherapeutics' management efficiency ratios could be used to measure how well SAB Biotherapeutics manages its routine affairs as well as how well it operates its assets and liabilities.SAB Biotherapeutics currently holds 5.91 M in liabilities with Debt to Equity (D/E) ratio of 0.16, which may suggest the company is not taking enough advantage from borrowing. SAB Biotherapeutics has a current ratio of 1.69, which is within standard range for the sector. Note, when we think about SAB Biotherapeutics' use of debt, we should always consider it together with its cash and equity.
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies. The company was founded in 2014 and is based in Sioux Falls, South Dakota. Sab Biotherapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 1 people. SAB Biotherapeutics (SABS) is traded on NASDAQ Exchange in USA. It is located in 777 W 41st St., Miami Beach, FL, United States, 33140 and employs 57 people. SAB Biotherapeutics is listed under Biotechnology category by Fama And French industry classification. Management Performance
| Return On Equity | -1.75 | ||||
| Return On Asset | -0.79 |
SAB Biotherapeutics Leadership Team
Elected by the shareholders, the SAB Biotherapeutics' board of directors comprises two types of representatives: SAB Biotherapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of SAB. The board's role is to monitor SAB Biotherapeutics' management team and ensure that shareholders' interests are well served. SAB Biotherapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, SAB Biotherapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| MBA CMA, Ex CFO | ||
| MD MBA, Executive Officer | ||
| Mark Conley, Interim Officer | ||
| Eddie Sullivan, President, CoFounder | ||
| Carlos Carillo, Senior Affairs | ||
| Lucy To, EVP CFO | ||
| Christoph MBA, Executive COO | ||
| Michael King, EVP CFO | ||
| Samuel Reich, Executive Chairman | ||
| Christine MBA, CoFounder Director | ||
| Edward DVM, CoFounder Observer |
SAB Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is SAB Biotherapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.75 | ||||
| Return On Asset | -0.79 | ||||
| Operating Margin | (34.23) % | ||||
| Current Valuation | (11.58 M) | ||||
| Shares Outstanding | 9.23 M | ||||
| Shares Owned By Insiders | 19.15 % | ||||
| Shares Owned By Institutions | 28.68 % | ||||
| Number Of Shares Shorted | 67.69 K | ||||
| Price To Book | 0.39 X | ||||
| Price To Sales | 9.88 X |
Thematic Opportunities
Explore Investment Opportunities
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics. You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.
Other Tools for SAB Stock
When running SAB Biotherapeutics' price analysis, check to measure SAB Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy SAB Biotherapeutics is operating at the current time. Most of SAB Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of SAB Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move SAB Biotherapeutics' price. Additionally, you may evaluate how the addition of SAB Biotherapeutics to your portfolios can decrease your overall portfolio volatility.
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope |